BISPECTRA

100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

Effective Date:	7-Feb-2018	7-Feb-2021	: Date of Next Review
Prepared By:	Jamie Storm	16-001146 v.1.0	: Supersedes
QA/QC Approval:	Nicole Fisher	Dora Meissner	: Management Approval
Reason for Revision:	See Revision History in ensur		

GUANIDINE HYDROCHLORIDE Certificate of Analysis BIO EXCIPIENT GRADE / GH3220 – K001 Lot#: GH3220-013-0419

NH₂C(NH)NH₂·HCl \star F.W. 95.53 g /mol. \star CAS# 50-01-1 Manufacturing Date: 9/21/2018 Retest Date: 9/30/2020 Manufacturing Site: 1474 Rockdale Lane, Stroudsburg, PA 18360 Packaging Date: 4/17/2019 Packaging Site: 100 Majestic Way, Bangor PA, 18013

Analysis		SPECIFICATIONS	RESULT	
	230 nm	0.2000 a.u. max.	0.1086 a.u.	
Absorbance (6M)	260 nm	0.0300 a.u. max.	0.0078 a.u.	
	275 nm	0.0300 a.u. max.	0.0031 a.u.	
Appearance and Color		White / Crystals	White / Crystals	
Assay		99.5% min.	100.04%	
	DNase	None Detected	None Detected	
Enzymes	Protease	None Detected	None Detected	
	RNase	None Detected	None Detected	
Identification (IR)		Passes Test	Passes Test	
Insoluble Matter		0.15% max.	<0.0004%	
Loss on Drying		0.5% max.	0.0449%	
Melting Range		184-188°C	185.3 – 186.6 °C	
Nitrate		0.01% max.	<0.01%	
pH (6M)		4.5-6.0	5.05 @ 24.2 °C	
Residue on Ignition		0.05% max.	<0.0100%	
Solubility (6M)		Passes Test	Passes Test	
Sulfate		0.01% max.	<0.01%	
	Arsenic (As)	5 ppm max.	< 5 ppm	
	Copper (Cu)	5 ppm max.	< 5 ppm	
Trace Metals	Iron (Fe)	5 ppm max.	< 5 ppm	
	Lead (Pb)	5 ppm max.	< 5 ppm	

COUNTRY OF ORIGIN: U.S.A.

The information contained herein is the property of BioSpectra. The recipient is responsible for its safe-keeping, and the prevention of unauthorized appropriation, use, disclosure and copying,

TEST METHOD REFERENCE: DCN: 16-000493

<u>INTENDED USE:</u> Material Represented by this Certificate of Analysis is suitable to be used only as the following: ICH Q7 Compliant cGMP Manufactured Excipient, for use in further Manufacturing. The material represented by this Certificate of Analysis is not suitable to be used as an Active Pharmaceutical Ingredient, Drug Product or Household Item.

<u>OVI STATEMENT</u>: Based on the manufacturing process and the controlled handling and storage of this product, there is no potential for any of the residual solvents listed in the current USP method <467> Tables 1, 2, 3, or 4 to be present at the specified limits; furthermore, if tested this product would comply with USP/NF requirements.

Prepared by:	Com	Date:	4/18/19
Reviewed by:	A. burn	Date:	4118/19